What biomarker tests are recommended for Esophageal Cancer

Biomarker Testing for Esophageal Cancer

According to the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers (Version 4.2025), there are several important biomarker tests that should be performed for newly diagnosed esophageal cancer patients. Let me break down what these tests are and why they matter.

Universal Testing (Recommended for All Patients)

These tests should be performed on all newly diagnosed esophageal and esophagogastric junction cancer patients:

1. PD-L1 Testing

• What it measures: PD-L1 is a protein on cancer cells that helps them hide from the immune system
• How it's measured: Using immunohistochemistry (IHC) - a staining technique on tissue samples
• Why it matters: A positive PD-L1 result (Combined Positive Score ≥1) may indicate that immunotherapy drugs (checkpoint inhibitors) could be effective for your cancer
• Clinical significance: This helps determine if you're a candidate for PD-1/PD-L1 inhibitor treatments

2. Microsatellite Instability (MSI) or Mismatch Repair (MMR) Testing

• What it measures: Whether your cancer cells have defects in their DNA repair systems
• How it's measured: Either by PCR/NGS (looking for MSI) or IHC (looking for MMR protein loss)
• Why it matters: MSI-High (MSI-H) or deficient MMR (dMMR) tumors often respond well to immunotherapy
• Important note: According to NCCN, patients with MSI-H or dMMR results should be referred to a genetics counselor for further assessment

3. HER2 Testing

• What it measures: Whether your cancer cells have too many copies of the HER2 gene (amplification) or overexpress the HER2 protein
• How it's measured: First with immunohistochemistry (IHC), then with fluorescence in situ hybridization (FISH) if the IHC result is equivocal (2+)
• Why it matters: HER2-positive cancers can be treated with targeted therapies like trastuzumab (Herceptin)
• Scoring: Results are scored as 0, 1+, 2+ (equivocal), or 3+ (positive)

4. CLDN18.2 Testing

• What it measures: Claudin 18 isoform 2, a protein found on the surface of cancer cells
• How it's measured: Using immunohistochemistry on tissue samples
• Positive result: ≥75% of tumor cells showing moderate to strong membrane staining
• Why it matters: CLDN18.2-positive cancers may respond to zolbetuximab, a targeted therapy drug

Additional Testing to Consider

5. Next-Generation Sequencing (NGS)

• What it is: A comprehensive test that analyzes multiple genes simultaneously
• When it's used: According to NCCN, NGS can be considered:
  • Later in the clinical course if sufficient tumor tissue is available
  • When limited tissue is available for initial testing
  • For patients with metastatic or advanced cancer who cannot undergo traditional biopsy
• What it can detect: Multiple biomarkers including:
  • HER2 amplification
  • Tumor mutational burden (TMB)
  • NTRK gene fusions
  • RET gene fusions
  • BRAF V600E mutations
  • MSI status

6. Liquid Biopsy (Blood-Based Testing)

• What it is: Testing for circulating tumor DNA (ctDNA) in your blood
• When it's used: For patients with limited tissue available or those unable to undergo traditional biopsy
• Why it matters: Can identify targetable genetic changes and track how your cancer evolves during treatment
• Important limitation: A negative result should be interpreted carefully—it doesn't completely rule out the presence of tumor mutations

How Testing is Performed

According to NCCN Guidelines:

• Preferred initial approach: IHC (immunohistochemistry), ISH (in situ hybridization), or targeted PCR
• Tissue source: Formalin-fixed paraffin-embedded (FFPE) tissue from biopsies or surgical specimens
• Laboratory requirement: All testing must be performed in CLIA-approved laboratories (Clinical Laboratory Improvement Amendments certified)
• Minimum tissue requirement: At least 100 tumor cells must be present for adequate PD-L1 evaluation

Why These Tests Matter for Your Treatment

These biomarker results help your oncology team:

• Select targeted therapies that work specifically against your cancer's molecular characteristics
• Predict treatment response to immunotherapy or other precision medicines
• Identify genetic counseling needs (especially for MSI-H/dMMR results)
• Monitor disease progression through repeat testing if your cancer advances

Questions to Ask Your Healthcare Team

1. Which biomarker tests have been performed on my cancer tissue?
2. What were my specific results for PD-L1, MSI/MMR, HER2, and CLDN18.2?
3. Based on my biomarker results, what treatment options are available to me?
4. If my initial tissue sample was limited, should we consider NGS or liquid biopsy testing?
5. Will my biomarkers be retested if my cancer progresses or if I develop resistance to treatment?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.